Research programme: apolipoprotein E mimetic peptides - LipimetiX Development

Drug Profile

Research programme: apolipoprotein E mimetic peptides - LipimetiX Development

Alternative Names: AEM 28 02; AEM-28-14

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator University of Alabama at Birmingham
  • Developer LipimetiX Development
  • Class Peptides
  • Mechanism of Action Apolipoprotein E agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hypercholesterolaemia
  • Research Coronary artery disease; Peripheral arterial disorders

Most Recent Events

  • 19 Dec 2016 Pharmacodynamics data from preclinial studies inHypercholesterolaemia released by LipimetiX Development
  • 25 Aug 2016 LipimetiX Development plans phase-I and phase-II trials for hypercholesterolemia and hypertriglyceridemia
  • 15 Dec 2015 Interim pharmacodynamics and adverse events data from a preclinical studies in Hypercholesterolaemia released by LipimetiX
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top